Last Updated: November 7, 2026

Expiring Drug Patents Cheat Sheet
We analyse the patents covering drugs in 134 countries and quickly give you the likely loss-of-exclusivity/generic entry date

➤ Get the Full List

United States: These 65 Drugs Face Patent Expirations and Generic Entry From 2026 - 2027

The content of this page is licensed under a Creative Commons Attribution 4.0 International License. Creative Commons License

Generic Entry Dates in Other Countries

African Regional IP Organization (ARIPO) Argentina Australia Austria Brazil Canada Chile China Colombia Costa Rica Croatia Cuba Cyprus Denmark Dominican Republic Ecuador El Salvador Eurasian Patent Organization European Patent Office Finland France Georgia, Republic of Germany Guatemala Honduras Hong Kong Hungary Israel Italy Japan Jordan Lithuania Luxembourg Malaysia Mexico Montenegro Morocco Netherlands New Zealand Nicaragua Norway Panama Peru Philippines Poland Portugal Russian Federation San Marino Saudi Arabia Serbia Singapore Slovenia South Africa South Korea Spain Taiwan Tunisia Turkey Ukraine United Kingdom Uruguay
Preferred citation:
Friedman, Yali, "United States: These 65 Drugs Face Patent Expirations and Generic Entry From 2026 - 2027" DrugPatentWatch.com thinkBiotech, 2026 www.drugpatentwatch.com/p/expiring-drug-patents-generic-entry/.
Media collateral
These estimated drug patent expiration dates and generic entry opportunity dates are calculated from analysis of known patents covering drugs. Many factors can influence early or late generic entry. This information is provided as a rough estimate of generic entry potential and should not be used as an independent source. The methodology is described in this blog post.
When can BEVYXXA (betrixaban) generic drug versions launch in the United States?

Generic name: betrixaban
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 08, 2026
Generic Entry Controlled by: United States Patent Patent 7,598,276

BEVYXXA is a drug marketed by Portola Pharms Inc. There are five patents protecting this drug. There has been litigation on patents covering BEVYXXA

See drug price trends for BEVYXXA.

The generic ingredient in BEVYXXA is betrixaban. Additional details are available on the betrixaban profile page.

When can EXPAREL (bupivacaine) generic drug versions launch in the United States?

Generic name: bupivacaine
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 09, 2026
Generic Entry Controlled by: United States FDA Regulatory Exclusivity

EXPAREL is a drug marketed by Pacira Pharms Inc. There are twenty-three patents protecting this drug. There has been litigation on patents covering EXPAREL

See drug price trends for EXPAREL.

The generic ingredient in EXPAREL is bupivacaine. Additional details are available on the bupivacaine profile page.

When can HORIZANT (gabapentin enacarbil) generic drug versions launch in the United States?

Generic name: gabapentin enacarbil
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 10, 2026
Generic Entry Controlled by: United States Patent Patent 8,026,279

HORIZANT is a drug marketed by Azurity. There are three patents protecting this drug. One tentatively approved generic is ready to enter the market. There has been litigation on patents covering HORIZANT

See drug price trends for HORIZANT.

The generic ingredient in HORIZANT is gabapentin enacarbil. Additional details are available on the gabapentin enacarbil profile page.

When can IZERVAY (avacincaptad pegol sodium) generic drug versions launch in the United States?

Generic name: avacincaptad pegol sodium
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 11, 2026
Generic Entry Controlled by: United States Patent Patent 8,236,773

IZERVAY is a drug marketed by Astellas. There are six patents protecting this drug.

See drug price trends for IZERVAY.

The generic ingredient in IZERVAY is avacincaptad pegol sodium. Additional details are available on the avacincaptad pegol sodium profile page.

When can GIVLAARI (givosiran sodium) generic drug versions launch in the United States?

Generic name: givosiran sodium
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 20, 2026
Generic Entry Controlled by: United States FDA Regulatory Exclusivity

GIVLAARI is a drug marketed by Alnylam Pharms Inc. There are eight patents protecting this drug. There has been litigation on patents covering GIVLAARI

See drug price trends for GIVLAARI.

The generic ingredient in GIVLAARI is givosiran sodium. Additional details are available on the givosiran sodium profile page.

When can AXUMIN (fluciclovine f-18) generic drug versions launch in the United States?

Generic name: fluciclovine f-18
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 28, 2026
Generic Entry Controlled by: United States Patent Patent 10,010,632

AXUMIN is a drug marketed by Blue Earth. There are eight patents protecting this drug. There has been litigation on patents covering AXUMIN

The generic ingredient in AXUMIN is fluciclovine f-18. Additional details are available on the fluciclovine f-18 profile page.

When can ZUNVEYL (benzgalantamine gluconate) generic drug versions launch in the United States?

Generic name: benzgalantamine gluconate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 01, 2026
Generic Entry Controlled by: United States Patent Patent 9,763,953

ZUNVEYL is a drug marketed by Alpha Cognition. There are four patents protecting this drug. There has been litigation on patents covering ZUNVEYL

The generic ingredient in ZUNVEYL is benzgalantamine gluconate. Additional details are available on the benzgalantamine gluconate profile page.

When can VYONDYS 53 (golodirsen) generic drug versions launch in the United States?

Generic name: golodirsen
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 12, 2026
Generic Entry Controlled by: United States FDA Regulatory Exclusivity

VYONDYS 53 is a drug marketed by Sarepta Theraps Inc. There is one patent protecting this drug. There has been litigation on patents covering VYONDYS 53

The generic ingredient in VYONDYS 53 is golodirsen. Additional details are available on the golodirsen profile page.

When can SIGNIFOR (pasireotide diaspartate) generic drug versions launch in the United States?

Generic name: pasireotide diaspartate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 14, 2026
Generic Entry Controlled by: United States Patent Patent 7,473,761

SIGNIFOR is a drug marketed by Recordati Rare. There are three patents protecting this drug.

See drug price trends for SIGNIFOR.

The generic ingredient in SIGNIFOR is pasireotide diaspartate. Additional details are available on the pasireotide diaspartate profile page.

When can VYNDAMAX (tafamidis) generic drug versions launch in the United States?

Generic name: tafamidis
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 19, 2026
Generic Entry Controlled by: United States Patent Patent 7,214,695

VYNDAMAX is a drug marketed by Foldrx Pharms. There are three patents protecting this drug. There has been litigation on patents covering VYNDAMAX

See drug price trends for VYNDAMAX.

The generic ingredient in VYNDAMAX is tafamidis. Additional details are available on the tafamidis profile page.

When can VYNDAQEL (tafamidis meglumine) generic drug versions launch in the United States?

Generic name: tafamidis meglumine
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 19, 2026
Generic Entry Controlled by: United States Patent Patent 7,214,695

VYNDAQEL is a drug marketed by Foldrx Pharms. There are two patents protecting this drug. There has been litigation on patents covering VYNDAQEL

See drug price trends for VYNDAQEL.

The generic ingredient in VYNDAQEL is tafamidis meglumine. Additional details are available on the tafamidis meglumine profile page.

When can EPANOVA (omega-3-carboxylic acids) generic drug versions launch in the United States?

Generic name: omega-3-carboxylic acids
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 20, 2026
Generic Entry Controlled by: United States Patent Patent 7,960,370

EPANOVA is a drug marketed by Astrazeneca. There are four patents protecting this drug.

The generic ingredient in EPANOVA is omega-3-carboxylic acids. Additional details are available on the omega-3-carboxylic acids profile page.

When can TISSUEBLUE (brilliant blue g) generic drug versions launch in the United States?

Generic name: brilliant blue g
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 20, 2026
Generic Entry Controlled by: United States FDA Regulatory Exclusivity

TISSUEBLUE is a drug marketed by Dutch Ophthalmic.

The generic ingredient in TISSUEBLUE is brilliant blue g. Additional details are available on the brilliant blue g profile page.

When can SYMTUZA (cobicistat; darunavir; emtricitabine; tenofovir alafenamide fumarate) generic drug versions launch in the United States?

Generic name: cobicistat; darunavir; emtricitabine; tenofovir alafenamide fumarate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 26, 2026
Generic Entry Controlled by: United States Patent Patent 7,700,645

Drug Price Trends for SYMTUZA
SYMTUZA is a drug marketed by Janssen Prods. There are six patents protecting this drug. There has been litigation on patents covering SYMTUZA

See drug price trends for SYMTUZA.

The generic ingredient in SYMTUZA is cobicistat; darunavir; emtricitabine; tenofovir alafenamide fumarate. Additional details are available on the cobicistat; darunavir; emtricitabine; tenofovir alafenamide fumarate profile page.

When can VIBATIV (telavancin hydrochloride) generic drug versions launch in the United States?

Generic name: telavancin hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: January 01, 2027
Generic Entry Controlled by: United States Patent Patent 7,531,623

VIBATIV is a drug marketed by Apotex. There is one patent protecting this drug.

See drug price trends for VIBATIV.

The generic ingredient in VIBATIV is telavancin hydrochloride. Additional details are available on the telavancin hydrochloride profile page.

When can PIQRAY (alpelisib) generic drug versions launch in the United States?

Generic name: alpelisib
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: January 18, 2027
Generic Entry Controlled by: United States FDA Regulatory Exclusivity

PIQRAY is a drug marketed by Novartis. There are two patents protecting this drug.

See drug price trends for PIQRAY.

The generic ingredient in PIQRAY is alpelisib. Additional details are available on the alpelisib profile page.

When can STIOLTO RESPIMAT (olodaterol hydrochloride; tiotropium bromide) generic drug versions launch in the United States?

Generic name: olodaterol hydrochloride; tiotropium bromide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: January 19, 2027
Generic Entry Controlled by: United States Patent Patent 7,727,984

STIOLTO RESPIMAT is a drug marketed by Boehringer Ingelheim. There are five patents protecting this drug. There has been litigation on patents covering STIOLTO RESPIMAT

See drug price trends for STIOLTO RESPIMAT.

The generic ingredient in STIOLTO RESPIMAT is olodaterol hydrochloride; tiotropium bromide. Additional details are available on the olodaterol hydrochloride; tiotropium bromide profile page.

When can STRIVERDI RESPIMAT (olodaterol hydrochloride) generic drug versions launch in the United States?

Generic name: olodaterol hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: January 19, 2027
Generic Entry Controlled by: United States Patent Patent 7,727,984

STRIVERDI RESPIMAT is a drug marketed by Boehringer Ingelheim. There is one patent protecting this drug. There has been litigation on patents covering STRIVERDI RESPIMAT

See drug price trends for STRIVERDI RESPIMAT.

The generic ingredient in STRIVERDI RESPIMAT is olodaterol hydrochloride. Additional details are available on the olodaterol hydrochloride profile page.

When can KYNAMRO (mipomersen sodium) generic drug versions launch in the United States?

Generic name: mipomersen sodium
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: January 29, 2027
Generic Entry Controlled by: United States Patent Patent 7,511,131

KYNAMRO is a drug marketed by Kastle Theraps Llc. There is one patent protecting this drug. There has been litigation on patents covering KYNAMRO

See drug price trends for KYNAMRO.

The generic ingredient in KYNAMRO is mipomersen sodium. Additional details are available on the mipomersen sodium profile page.

When can LEGUBETI (acetylcysteine lysine) generic drug versions launch in the United States?

Generic name: acetylcysteine lysine
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 13, 2027
Generic Entry Controlled by: United States FDA Regulatory Exclusivity

LEGUBETI is a drug marketed by Galephar.

The generic ingredient in LEGUBETI is acetylcysteine lysine. Additional details are available on the acetylcysteine lysine profile page.

When can ADVIL ALLERGY SINUS (chlorpheniramine maleate; ibuprofen; pseudoephedrine hydrochloride) generic drug versions launch in the United States?

Generic name: chlorpheniramine maleate; ibuprofen; pseudoephedrine hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 28, 2027
Generic Entry Controlled by: United States Patent Patent 7,863,287

ADVIL ALLERGY SINUS is a drug marketed by Haleon Us Holdings. There is one patent protecting this drug.

The generic ingredient in ADVIL ALLERGY SINUS is chlorpheniramine maleate; ibuprofen; pseudoephedrine hydrochloride. Additional details are available on the chlorpheniramine maleate; ibuprofen; pseudoephedrine hydrochloride profile page.

When can DUAVEE (bazedoxifene acetate; estrogens, conjugated) generic drug versions launch in the United States?

Generic name: bazedoxifene acetate; estrogens, conjugated
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 10, 2027
Generic Entry Controlled by: United States Patent Patent 7,683,051

Drug Price Trends for DUAVEE
DUAVEE is a drug marketed by Wyeth Pharms. There is one patent protecting this drug.

See drug price trends for DUAVEE.

The generic ingredient in DUAVEE is bazedoxifene acetate; estrogens, conjugated. Additional details are available on the bazedoxifene acetate; estrogens, conjugated profile page.

When can LIVMARLI (maralixibat chloride) generic drug versions launch in the United States?

Generic name: maralixibat chloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 13, 2027
Generic Entry Controlled by: United States FDA Regulatory Exclusivity

LIVMARLI is a drug marketed by Mirum. There are ten patents protecting this drug. There has been litigation on patents covering LIVMARLI

See drug price trends for LIVMARLI.

The generic ingredient in LIVMARLI is maralixibat chloride. Additional details are available on the maralixibat chloride profile page.

When can AVEED (testosterone undecanoate) generic drug versions launch in the United States?

Generic name: testosterone undecanoate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 14, 2027
Generic Entry Controlled by: United States Patent Patent 7,718,640

AVEED is a drug marketed by Endo Operations. There are two patents protecting this drug and one Paragraph IV challenge. One tentatively approved generic is ready to enter the market. There has been litigation on patents covering AVEED

See drug price trends for AVEED.

The generic ingredient in AVEED is testosterone undecanoate. Additional details are available on the testosterone undecanoate profile page.

When can DYANAVEL XR 10 (amphetamine; amphetamine aspartate/dextroamphetamine sulfate) generic drug versions launch in the United States?

Generic name: amphetamine; amphetamine aspartate/dextroamphetamine sulfate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 15, 2027
Generic Entry Controlled by: United States Patent Patent 8,747,902

DYANAVEL XR 10 is a drug marketed by Tris Pharma Inc. There are six patents protecting this drug.

The generic ingredient in DYANAVEL XR 10 is amphetamine; amphetamine aspartate/dextroamphetamine sulfate. Additional details are available on the amphetamine; amphetamine aspartate/dextroamphetamine sulfate profile page.

When can VICTRELIS (boceprevir) generic drug versions launch in the United States?

Generic name: boceprevir
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 17, 2027
Generic Entry Controlled by: United States Patent Patent 8,119,602

VICTRELIS is a drug marketed by Merck Sharp Dohme. There are two patents protecting this drug.

The generic ingredient in VICTRELIS is boceprevir. Additional details are available on the boceprevir profile page.

When can VARUBI (rolapitant hydrochloride) generic drug versions launch in the United States?

Generic name: rolapitant hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: April 04, 2027
Generic Entry Controlled by: United States Patent Patent 8,178,550

VARUBI is a drug marketed by Tersera. There are eight patents protecting this drug.

The generic ingredient in VARUBI is rolapitant hydrochloride. Additional details are available on the rolapitant hydrochloride profile page.

When can SAVAYSA (edoxaban tosylate) generic drug versions launch in the United States?

Generic name: edoxaban tosylate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: April 18, 2027
Generic Entry Controlled by: United States Patent Patent 7,365,205

Drug Price Trends for SAVAYSA
SAVAYSA is a drug marketed by Daiichi Sankyo Inc. There are two patents protecting this drug and one Paragraph IV challenge. There has been litigation on patents covering SAVAYSA

See drug price trends for SAVAYSA.

The generic ingredient in SAVAYSA is edoxaban tosylate. Additional details are available on the edoxaban tosylate profile page.

When can CHLORAPREP ONE-STEP (chlorhexidine gluconate; isopropyl alcohol) generic drug versions launch in the United States?

Generic name: chlorhexidine gluconate; isopropyl alcohol
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: April 25, 2027
Generic Entry Controlled by: United States Patent Patent 7,422,388

CHLORAPREP ONE-STEP is a drug marketed by Becton Dickinson Co.

The generic ingredient in CHLORAPREP ONE-STEP is chlorhexidine gluconate; isopropyl alcohol. Additional details are available on the chlorhexidine gluconate; isopropyl alcohol profile page.

When can GENVOYA (cobicistat; elvitegravir; emtricitabine; tenofovir alafenamide fumarate) generic drug versions launch in the United States?

Generic name: cobicistat; elvitegravir; emtricitabine; tenofovir alafenamide fumarate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: April 26, 2027
Generic Entry Controlled by: United States Patent Patent 8,981,103

GENVOYA is a drug marketed by Gilead Sciences Inc. There are nine patents protecting this drug. There has been litigation on patents covering GENVOYA

See drug price trends for GENVOYA.

The generic ingredient in GENVOYA is cobicistat; elvitegravir; emtricitabine; tenofovir alafenamide fumarate. Additional details are available on the cobicistat; elvitegravir; emtricitabine; tenofovir alafenamide fumarate profile page.

When can STRIBILD (cobicistat; elvitegravir; emtricitabine; tenofovir disoproxil fumarate) generic drug versions launch in the United States?

Generic name: cobicistat; elvitegravir; emtricitabine; tenofovir disoproxil fumarate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: April 26, 2027
Generic Entry Controlled by: United States Patent Patent 8,981,103

STRIBILD is a drug marketed by Gilead Sciences Inc. There are seven patents protecting this drug and one Paragraph IV challenge. There has been litigation on patents covering STRIBILD

See drug price trends for STRIBILD.

The generic ingredient in STRIBILD is cobicistat; elvitegravir; emtricitabine; tenofovir disoproxil fumarate. Additional details are available on the cobicistat; elvitegravir; emtricitabine; tenofovir disoproxil fumarate profile page.

When can VITEKTA (elvitegravir) generic drug versions launch in the United States?

Generic name: elvitegravir
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: April 26, 2027
Generic Entry Controlled by: United States Patent Patent 8,981,103

VITEKTA is a drug marketed by Gilead Sciences Inc. There are three patents protecting this drug. One tentatively approved generic is ready to enter the market. There has been litigation on patents covering VITEKTA

The generic ingredient in VITEKTA is elvitegravir. Additional details are available on the elvitegravir profile page.

When can AMYVID (florbetapir f-18) generic drug versions launch in the United States?

Generic name: florbetapir f-18
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: April 30, 2027
Generic Entry Controlled by: United States Patent Patent 7,687,052

AMYVID is a drug marketed by Avid Radiopharms Inc. There are two patents protecting this drug. There has been litigation on patents covering AMYVID

The generic ingredient in AMYVID is florbetapir f-18. Additional details are available on the florbetapir f-18 profile page.

When can VELTASSA (patiromer sorbitex calcium) generic drug versions launch in the United States?

Generic name: patiromer sorbitex calcium
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 29, 2027
Generic Entry Controlled by: United States Patent Patent 8,282,913

Drug Price Trends for VELTASSA
VELTASSA is a drug marketed by Vifor Pharma. There are seven patents protecting this drug. There has been litigation on patents covering VELTASSA

See drug price trends for VELTASSA.

The generic ingredient in VELTASSA is patiromer sorbitex calcium. Additional details are available on the patiromer sorbitex calcium profile page.

When can CONTRAVE (bupropion hydrochloride; naltrexone hydrochloride) generic drug versions launch in the United States?

Generic name: bupropion hydrochloride; naltrexone hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 04, 2027
Generic Entry Controlled by: United States Patent Patent 9,107,837

CONTRAVE is a drug marketed by Azurity. There are eighteen patents protecting this drug and one Paragraph IV challenge. There has been litigation on patents covering CONTRAVE

See drug price trends for CONTRAVE.

The generic ingredient in CONTRAVE is bupropion hydrochloride; naltrexone hydrochloride. Additional details are available on the bupropion hydrochloride; naltrexone hydrochloride profile page.

When can EMBEDA (morphine sulfate; naltrexone hydrochloride) generic drug versions launch in the United States?

Generic name: morphine sulfate; naltrexone hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 19, 2027
Generic Entry Controlled by: United States Patent Patent 8,158,156

EMBEDA is a drug marketed by Alpharma Pharms. There are seven patents protecting this drug and four Paragraph IV challenges.

See drug price trends for EMBEDA.

The generic ingredient in EMBEDA is morphine sulfate; naltrexone hydrochloride. Additional details are available on the morphine sulfate; naltrexone hydrochloride profile page.

When can PREZCOBIX (cobicistat; darunavir) generic drug versions launch in the United States?

Generic name: cobicistat; darunavir
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 26, 2027
Generic Entry Controlled by: United States Patent Patent 7,700,645

Drug Price Trends for PREZCOBIX
PREZCOBIX is a drug marketed by Janssen Prods. There are three patents protecting this drug. There has been litigation on patents covering PREZCOBIX

See drug price trends for PREZCOBIX.

The generic ingredient in PREZCOBIX is cobicistat; darunavir. Additional details are available on the cobicistat; darunavir profile page.

When can PARAGARD T 380A (copper) generic drug versions launch in the United States?

Generic name: copper
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 28, 2027
Generic Entry Controlled by: United States FDA Regulatory Exclusivity

PARAGARD T 380A is a drug marketed by Coopersurgical.

The generic ingredient in PARAGARD T 380A is copper. Additional details are available on the copper profile page.

When can DOJOLVI (triheptanoin) generic drug versions launch in the United States?

Generic name: triheptanoin
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 30, 2027
Generic Entry Controlled by: United States FDA Regulatory Exclusivity

DOJOLVI is a drug marketed by Ultragenyx Pharm Inc. There are two patents protecting this drug. There has been litigation on patents covering DOJOLVI

See drug price trends for DOJOLVI.

The generic ingredient in DOJOLVI is triheptanoin. Additional details are available on the triheptanoin profile page.

When can PICATO (ingenol mebutate) generic drug versions launch in the United States?

Generic name: ingenol mebutate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: July 06, 2027
Generic Entry Controlled by: United States Patent Patent 8,278,292

Drug Price Trends for PICATO
PICATO is a drug marketed by Leo Labs. There are twelve patents protecting this drug and one Paragraph IV challenge. One tentatively approved generic is ready to enter the market. There has been litigation on patents covering PICATO

See drug price trends for PICATO.

The generic ingredient in PICATO is ingenol mebutate. Additional details are available on the ingenol mebutate profile page.

When can BYFAVO (remimazolam besylate) generic drug versions launch in the United States?

Generic name: remimazolam besylate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: July 10, 2027
Generic Entry Controlled by: United States Patent Patent 9,777,007

BYFAVO is a drug marketed by Acacia. There are eleven patents protecting this drug. There has been litigation on patents covering BYFAVO

See drug price trends for BYFAVO.

The generic ingredient in BYFAVO is remimazolam besylate. Additional details are available on the remimazolam besylate profile page.

When can EPIDIOLEX (cannabidiol) generic drug versions launch in the United States?

Generic name: cannabidiol
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: July 31, 2027
Generic Entry Controlled by: United States FDA Regulatory Exclusivity

EPIDIOLEX is a drug marketed by Jazz Pharms Res. There are thirty-three patents protecting this drug. There has been litigation on patents covering EPIDIOLEX

See drug price trends for EPIDIOLEX.

The generic ingredient in EPIDIOLEX is cannabidiol. Additional details are available on the cannabidiol profile page.

When can RELISTOR (methylnaltrexone bromide) generic drug versions launch in the United States?

Generic name: methylnaltrexone bromide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 03, 2027
Generic Entry Controlled by: United States Patent Patent 12,303,592

Drug Price Trends for RELISTOR
RELISTOR is a drug marketed by Salix Pharms and SalixThere are twelve patents protecting this drug and three Paragraph IV challenges. One tentatively approved generic is ready to enter the market. There has been litigation on patents covering RELISTOR

See drug price trends for RELISTOR.

The generic ingredient in RELISTOR is methylnaltrexone bromide. Additional details are available on the methylnaltrexone bromide profile page.

When can LAMPIT (nifurtimox) generic drug versions launch in the United States?

Generic name: nifurtimox
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 06, 2027
Generic Entry Controlled by: United States FDA Regulatory Exclusivity

LAMPIT is a drug marketed by Bayer Healthcare.

See drug price trends for LAMPIT.

The generic ingredient in LAMPIT is nifurtimox. Additional details are available on the nifurtimox profile page.

When can LYNPARZA (olaparib) generic drug versions launch in the United States?

Generic name: olaparib
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 12, 2027
Generic Entry Controlled by: United States Patent Patent 8,143,241

LYNPARZA is a drug marketed by Astrazeneca. There are twelve patents protecting this drug. Three tentatively approved generics are ready to enter the market. There has been litigation on patents covering LYNPARZA

See drug price trends for LYNPARZA.

The generic ingredient in LYNPARZA is olaparib. Additional details are available on the olaparib profile page.

When can VISTOGARD (uridine triacetate) generic drug versions launch in the United States?

Generic name: uridine triacetate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 17, 2027
Generic Entry Controlled by: United States Patent Patent 7,776,838

VISTOGARD is a drug marketed by Btg Intl. There is one patent protecting this drug.

See drug price trends for VISTOGARD.

The generic ingredient in VISTOGARD is uridine triacetate. Additional details are available on the uridine triacetate profile page.

When can NOURIANZ (istradefylline) generic drug versions launch in the United States?

Generic name: istradefylline
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: September 05, 2027
Generic Entry Controlled by: United States Patent Patent 8,318,201

NOURIANZ is a drug marketed by Kyowa Kirin. There are two patents protecting this drug. There has been litigation on patents covering NOURIANZ

See drug price trends for NOURIANZ.

The generic ingredient in NOURIANZ is istradefylline. Additional details are available on the istradefylline profile page.

When can SOLOSEC (secnidazole) generic drug versions launch in the United States?

Generic name: secnidazole
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: September 15, 2027
Generic Entry Controlled by: United States FDA Regulatory Exclusivity

Drug Price Trends for SOLOSEC
SOLOSEC is a drug marketed by Evofem Inc. There are eleven patents protecting this drug. There has been litigation on patents covering SOLOSEC

See drug price trends for SOLOSEC.

The generic ingredient in SOLOSEC is secnidazole. Additional details are available on the secnidazole profile page.

When can TYMLOS (abaloparatide) generic drug versions launch in the United States?

Generic name: abaloparatide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: October 03, 2027
Generic Entry Controlled by: United States Patent Patent 8,748,382

Drug Price Trends for TYMLOS
TYMLOS is a drug marketed by Radius. There are nine patents protecting this drug. There has been litigation on patents covering TYMLOS

See drug price trends for TYMLOS.

The generic ingredient in TYMLOS is abaloparatide. Additional details are available on the abaloparatide profile page.

When can BELEODAQ (belinostat) generic drug versions launch in the United States?

Generic name: belinostat
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: October 27, 2027
Generic Entry Controlled by: United States Patent Patent 8,835,501

BELEODAQ is a drug marketed by Acrotech Biopharma. There are two patents protecting this drug and one Paragraph IV challenge. There has been litigation on patents covering BELEODAQ

See drug price trends for BELEODAQ.

The generic ingredient in BELEODAQ is belinostat. Additional details are available on the belinostat profile page.

When can PYLARIFY (piflufolastat f-18) generic drug versions launch in the United States?

Generic name: piflufolastat f-18
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 07, 2027
Generic Entry Controlled by: United States Patent Patent 8,487,129

PYLARIFY is a drug marketed by Progenics Pharms Inc and AphelionThere are six patents protecting this drug.

See drug price trends for PYLARIFY.

The generic ingredient in PYLARIFY is piflufolastat f-18. Additional details are available on the piflufolastat f-18 profile page.

When can PYLARIFY TRUVU (piflufolastat f-18) generic drug versions launch in the United States?

Generic name: piflufolastat f-18
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 07, 2027
Generic Entry Controlled by: United States Patent Patent 8,487,129

PYLARIFY TRUVU is a drug marketed by Aphelion. There are six patents protecting this drug.

The generic ingredient in PYLARIFY TRUVU is piflufolastat f-18. Additional details are available on the piflufolastat f-18 profile page.

When can VARITHENA (polidocanol) generic drug versions launch in the United States?

Generic name: polidocanol
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 19, 2027
Generic Entry Controlled by: United States Patent Patent 7,814,943

VARITHENA is a drug marketed by Boston Scitfc. There are two patents protecting this drug.

See drug price trends for VARITHENA.

The generic ingredient in VARITHENA is polidocanol. Additional details are available on the polidocanol profile page.

When can ZOKINVY (lonafarnib) generic drug versions launch in the United States?

Generic name: lonafarnib
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 20, 2027
Generic Entry Controlled by: United States FDA Regulatory Exclusivity

ZOKINVY is a drug marketed by Sentynl Theraps Inc. There is one patent protecting this drug.

See drug price trends for ZOKINVY.

The generic ingredient in ZOKINVY is lonafarnib. Additional details are available on the lonafarnib profile page.

When can XERMELO (telotristat etiprate) generic drug versions launch in the United States?

Generic name: telotristat etiprate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 11, 2027
Generic Entry Controlled by: United States Patent Patent 7,553,840

XERMELO is a drug marketed by Tersera. There are five patents protecting this drug.

See drug price trends for XERMELO.

The generic ingredient in XERMELO is telotristat etiprate. Additional details are available on the telotristat etiprate profile page.

When can TROXYCA ER (naltrexone hydrochloride; oxycodone hydrochloride) generic drug versions launch in the United States?

Generic name: naltrexone hydrochloride; oxycodone hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 12, 2027
Generic Entry Controlled by: United States Patent Patent 7,815,934

TROXYCA ER is a drug marketed by Pfizer. There is one patent protecting this drug.

The generic ingredient in TROXYCA ER is naltrexone hydrochloride; oxycodone hydrochloride. Additional details are available on the naltrexone hydrochloride; oxycodone hydrochloride profile page.

When can INCRUSE ELLIPTA (umeclidinium bromide) generic drug versions launch in the United States?

Generic name: umeclidinium bromide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 18, 2027
Generic Entry Controlled by: United States Patent Patent 7,488,827

Drug Price Trends for INCRUSE ELLIPTA
INCRUSE ELLIPTA is a drug marketed by Glaxo Grp England. There is one patent protecting this drug. There has been litigation on patents covering INCRUSE ELLIPTA

See drug price trends for INCRUSE ELLIPTA.

The generic ingredient in INCRUSE ELLIPTA is umeclidinium bromide. Additional details are available on the umeclidinium bromide profile page.

When can ZEPBOUND (tirzepatide) generic drug versions launch in the United States?

Generic name: tirzepatide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 20, 2027
Generic Entry Controlled by: United States FDA Regulatory Exclusivity

Drug Price Trends for ZEPBOUND
ZEPBOUND is a drug marketed by Eli Lilly And Co. There are eight patents protecting this drug. There has been litigation on patents covering ZEPBOUND

See drug price trends for ZEPBOUND.

The generic ingredient in ZEPBOUND is tirzepatide. Additional details are available on the tirzepatide profile page.

When can SUNLENCA (lenacapavir sodium) generic drug versions launch in the United States?

Generic name: lenacapavir sodium
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 22, 2027
Generic Entry Controlled by: United States FDA Regulatory Exclusivity

SUNLENCA is a drug marketed by Gilead Sciences Inc. There are six patents protecting this drug.

See drug price trends for SUNLENCA.

The generic ingredient in SUNLENCA is lenacapavir sodium. Additional details are available on the lenacapavir sodium profile page.

When can XENOVIEW (xenon xe-129 hyperpolarized) generic drug versions launch in the United States?

Generic name: xenon xe-129 hyperpolarized
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 23, 2027
Generic Entry Controlled by: United States FDA Regulatory Exclusivity

XENOVIEW is a drug marketed by Polarean. There are two patents protecting this drug.

The generic ingredient in XENOVIEW is xenon xe-129 hyperpolarized. Additional details are available on the xenon xe-129 hyperpolarized profile page.

When can ZONTIVITY (vorapaxar sulfate) generic drug versions launch in the United States?

Generic name: vorapaxar sulfate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 23, 2027
Generic Entry Controlled by: United States Patent Patent 7,304,078

Drug Price Trends for ZONTIVITY
ZONTIVITY is a drug marketed by Key Therap. There is one patent protecting this drug.

See drug price trends for ZONTIVITY.

The generic ingredient in ZONTIVITY is vorapaxar sulfate. Additional details are available on the vorapaxar sulfate profile page.

Last updated: October 9, 2026

Executive summary: The U.S. drug market is divided between high-value branded products protected by patents, regulatory exclusivity, market access contracts and manufacturing complexity, and high-volume generics competing primarily on price. Generics account for about 90% of prescriptions but a substantially smaller share of spending. Brand companies retain value through lifecycle management, biologic switching barriers, specialty distribution, formulation patents and negotiated entry settlements. Generic and biosimilar companies face approval delays, patent litigation, manufacturing investment, supply-chain concentration and limited reimbursement differentiation. The strongest opportunities are in complex generics, biosimilars, sterile injectables, specialty medicines, authorized generics, contract manufacturing and products with expiring exclusivity. The largest risks are patent thickets, Medicare price negotiation, payer concentration, shortages and regulatory scrutiny of patent listings and settlement practices.

United States Branded and Generic Drug Markets: Regulatory Opportunities, Patent Risks and Commercial Outlook

How large is the U.S. branded and generic drug market?

The United States is the world’s largest pharmaceutical market by revenue and one of the most regulated markets for drug approval, pricing, reimbursement and promotion.

National health expenditures for prescription drugs reached approximately $467 billion in 2023, according to the Centers for Medicare & Medicaid Services (CMS). That figure includes retail prescription drugs and excludes several categories of products administered through hospitals and physician offices, including many biologics and infused medicines (CMS, 2024).

Generic drugs dominate utilization. The FDA reports that generic medicines account for approximately 90% of prescriptions dispensed in the United States, while branded products capture most prescription-drug spending because of higher prices, specialty products and biologic therapies (FDA, 2024a).

Market segment Primary products Main commercial driver Principal regulatory pathway
Branded small molecules New chemical entities, reformulations, specialty drugs Clinical differentiation and patent exclusivity NDA under Section 505
Generic small molecules Tablets, capsules, injectables, solutions Low cost and formulary access ANDA under Section 505(j)
Biologics Monoclonal antibodies, proteins, vaccines Clinical performance and manufacturing scale BLA under Section 351(a)
Biosimilars Follow-on biologics Price competition and interchangeability Section 351(k)
Complex generics Inhalers, long-acting injectables, ophthalmics, topical systems Technical barriers and limited competition ANDA or other FDA pathways
Authorized generics Brand product marketed without the brand name Controlled generic competition NDA-based commercialization

The commercial split is changing. Specialty medicines, oncology drugs, immunology products, rare-disease therapies and cell and gene therapies are taking a larger share of spending. Traditional oral medicines remain highly exposed to generic substitution after patent expiry.

When do branded drugs lose U.S. exclusivity?

A branded drug can lose exclusivity through patent expiration, regulatory exclusivity expiration, settlement agreements, authorized generic entry or a court decision invalidating or narrowing patent claims.

The relevant date is usually the earliest date on which a legally permissible competitor can obtain approval and enter the market. That date may differ from the nominal expiration date of the composition-of-matter patent.

Patent and regulatory exclusivity periods

Protection Typical term Commercial effect
Utility patent 20 years from earliest effective nonprovisional filing date Protects composition, formulation, use or manufacturing claims
Patent term adjustment Variable Adds time for certain USPTO delays
Patent term extension Up to 5 years Restores regulatory-review time, subject to statutory limits
New chemical entity exclusivity 5 years Blocks ANDA submission for most of the period
New clinical investigation exclusivity 3 years Protects approved changes supported by new clinical studies
Orphan-drug exclusivity 7 years Blocks approval for the same drug and disease indication
Pediatric exclusivity 6 months Extends listed patents and qualifying exclusivities
Biologic reference-product exclusivity 12 years Delays biosimilar approval under the BPCIA
Biosimilar first interchangeable product exclusivity Generally 12 months under current law and FDA interpretation Delays certain competing interchangeable products

The Hatch-Waxman framework allows an NDA holder to list qualifying patents in the FDA Orange Book. A generic applicant must address those patents through a Paragraph I, II, III or IV certification. A Paragraph IV certification alleges that the listed patent is invalid, unenforceable or will not be infringed.

A timely patent-infringement action following a Paragraph IV notice can trigger a 30-month stay of ANDA approval, subject to statutory exceptions and court decisions. The stay does not always prevent commercial entry if the litigation ends earlier or if the court determines that the stay has expired.

Patent term extension and pediatric extension

Patent term extension under 35 U.S.C. §156 can restore part of the period lost during FDA review. The extension applies to one patent covering the approved product and is limited by statutory caps.

Pediatric exclusivity under the FDA Amendments Act can add six months to qualifying patents and regulatory exclusivities. The six-month period often has greater commercial value than its duration suggests because it can delay generic entry across a high-revenue product.

What patents protect branded drugs in the United States?

The most valuable patent is usually the composition-of-matter patent, but later-filed patents can materially affect generic entry.

Main patent categories

  1. Composition patents cover the active pharmaceutical ingredient or a defined chemical class.
  2. Polymorph, salt and crystal-form patents cover specific physical or chemical forms.
  3. Formulation patents cover release profiles, excipients, particle sizes, delivery systems and stability characteristics.
  4. Method-of-use patents cover treatment of a disease, patient subgroup, dosing schedule or biomarker-defined population.
  5. Device patents cover autoinjectors, inhalers, prefilled syringes, pumps and delivery components.
  6. Manufacturing patents cover synthesis, purification, fermentation, crystallization and formulation processes.
  7. Diagnostic and companion patents may protect biomarker selection or treatment decisions.

Composition patents provide the strongest protection when claim scope is valid and commercially relevant. Formulation and method-of-use patents can delay competition, but they are more vulnerable to noninfringement arguments, design-arounds and limitations on the scope of an ANDA label.

The FDA’s Orange Book lists patents and exclusivities for approved small-molecule drugs. A patent may be commercially important without being listed in the Orange Book, particularly if it relates to manufacturing, a biologic process or technology outside the statutory listing rules.

How do Paragraph IV challenges affect generic entry?

Paragraph IV litigation is the primary legal route for accelerated generic entry before all listed patents expire.

A first applicant that submits a substantially complete ANDA with a Paragraph IV certification can qualify for 180-day generic drug exclusivity if it satisfies the statutory requirements. The exclusivity is shared or forfeitable in certain circumstances.

Generic launch scenarios

Scenario Likely entry outcome
No listed patent challenge Entry after patent and exclusivity expiry
Paragraph IV with no timely lawsuit FDA approval after the statutory process
Paragraph IV followed by litigation Approval may be delayed by the 30-month stay
Patent invalidated or not infringed Entry after approval and litigation resolution
Patent upheld Entry delayed until patent expiry or settlement date
Authorized generic launch Price pressure can begin before independent generic entry
Settlement with licensed entry Entry occurs on a negotiated date, often before patent expiry

Paragraph IV settlements remain subject to antitrust scrutiny. The Federal Trade Commission has challenged “pay-for-delay” agreements in which a brand company allegedly compensates a generic company to postpone entry. The Supreme Court held in FTC v. Actavis that reverse-payment agreements can violate antitrust law even when the settlement falls within the scope of the patent (FTC, 2024a; U.S. Supreme Court, 2013).

What is the Orange Book status of generic and branded drugs?

The Orange Book identifies FDA-approved drug products and relevant patent and exclusivity information for approved small-molecule drugs. It does not provide a complete record of every patent that may affect market entry.

For business planning, an Orange Book review should evaluate:

  • Listed patent number and expiration date.
  • Patent type and claim category.
  • Use code associated with method-of-use claims.
  • Whether the patent has been delisted or corrected.
  • Regulatory exclusivity expiration.
  • Paragraph IV notices and litigation records.
  • The applicant’s proposed label.
  • Potential skinny-label exposure.
  • Pediatric exclusivity and patent-term extension.
  • Whether a 30-month stay has been triggered.

The FDA and FTC have increased scrutiny of improper or overbroad Orange Book listings. In 2023 and 2024, the agencies required manufacturers to review patent listings and respond to concerns involving patents that may not satisfy statutory listing criteria (FDA, 2024b; FTC, 2024b).

What formulation patents protect branded drugs?

Formulation patents are particularly important after composition patents expire. They may protect:

  • Extended-release tablets.
  • Abuse-deterrent formulations.
  • Fixed-dose combinations.
  • Long-acting injectables.
  • Inhaled formulations.
  • Ophthalmic emulsions and suspensions.
  • Transdermal systems.
  • Injectable depot formulations.
  • Stabilized biologic compositions.
  • Device-drug combinations.

A formulation patent is commercially strongest when the formulation is necessary to achieve the approved product’s performance and cannot be easily designed around. Its value is weaker when a generic can use a different excipient system or delivery process while maintaining pharmaceutical equivalence and bioequivalence.

For complex products, FDA approval requirements can be as important as patent scope. A generic applicant may need comparative clinical endpoint studies, pharmacokinetic studies, device testing, in vitro characterization or specialized analytical methods.

How does the biosimilar market compare with the generic market?

Biosimilars operate under the Biologics Price Competition and Innovation Act, not the traditional ANDA pathway. A biosimilar applicant must demonstrate that its product is highly similar to the reference biologic and has no clinically meaningful differences in safety, purity and potency.

The key distinction is substitution. An FDA-designated interchangeable biosimilar may be substituted at the pharmacy level under applicable state law, while a non-interchangeable biosimilar generally requires prescriber or payer-driven switching.

Issue Generic drug Biosimilar
Reference product Small-molecule NDA product Biologic licensed under a BLA
Statutory pathway Section 505(j) ANDA Section 351(k)
Core standard Pharmaceutical equivalence and bioequivalence High similarity and no clinically meaningful differences
Automatic substitution Generally available under state law Depends on interchangeability designation and state law
Patent information Orange Book Patent disclosures and BPCIA litigation process
Manufacturing barrier Moderate for standard products High because of cell lines, analytics and process controls
Price competition Often rapid and severe Often slower and payer-driven
Main competitors Multiple generic applicants Smaller number of biosimilar manufacturers

The biosimilar opportunity is largest in oncology, immunology, ophthalmology, endocrinology and supportive care. The commercial barriers include physician familiarity, payer contracting, site-of-care economics, distribution arrangements, interchangeability requirements and reference-product contracting.

Biologic patent estates also tend to contain process, formulation, device and method-of-use claims. These patents can support negotiated launch dates even after the core biologic exclusivity period ends.

What FDA regulatory opportunities exist for generic and branded drug companies?

Generic drug opportunities

The FDA’s competitive generic therapy initiatives target products with limited competition or no approved generic equivalent. The agency has used guidance, product-specific recommendations and regulatory prioritization to encourage applications for drugs with market failures (FDA, 2024c).

Priority opportunities include:

  • Complex generics with limited approved competitors.
  • Sterile injectables exposed to shortages.
  • Inhaled and nasal products.
  • Ophthalmic products.
  • Transdermal and topical systems.
  • Long-acting injectable formulations.
  • Drug-device combinations.
  • Products with discontinued or withdrawn competitors.
  • Authorized generics and co-development arrangements.

The largest returns often occur before multiple competitors enter. Once several ANDAs are approved, prices can fall sharply.

Branded drug opportunities

Brand companies can pursue:

  • Orphan-drug designations.
  • Breakthrough Therapy and Fast Track designations.
  • Priority Review.
  • Accelerated Approval.
  • New indications supported by supplemental NDAs or BLAs.
  • Pediatric exclusivity.
  • Companion diagnostic strategies.
  • Formulation improvements.
  • Device integration.
  • Geographic licensing and co-commercialization.
  • Authorized generic programs.

The commercial risk is that accelerated approval can create postmarketing obligations and confirmatory-trial exposure. Failure to verify clinical benefit can lead to withdrawal proceedings or label restrictions.

What patent litigation affects the U.S. drug market?

The main litigation categories are:

  1. Paragraph IV ANDA litigation involving small-molecule products.
  2. BPCIA patent litigation involving biosimilars.
  3. Patent-term and patent-listing disputes.
  4. Antitrust claims involving reverse-payment settlements.
  5. Inter partes review and post-grant review proceedings before the Patent Trial and Appeal Board.
  6. Trade-secret litigation involving manufacturing processes.
  7. False-marking, inequitable-conduct and regulatory-fraud claims.
  8. State and federal claims involving delayed generic entry or restricted access.

The most important litigation variable is not the number of patents but the probability that at least one enforceable patent will block the proposed product. A single valid composition or formulation patent can prevent commercial entry even where the wider estate contains weak claims.

Which companies are challenging branded drug positions?

The U.S. competitive field includes large generic manufacturers such as Teva, Viatris, Sandoz, Amneal and Hikma, along with specialty and complex-generic companies including Alvogen, Lupin, Dr. Reddy’s Laboratories, Sun Pharma, Zydus and Endo’s former Par Pharmaceutical operations.

Biosimilar competition includes companies such as Amgen, Sandoz, Celltrion, Biocon Biologics, Samsung Bioepis, Organon, Pfizer and Teva, often through partnerships or regional commercialization agreements.

Brand companies increasingly use licensing and acquisition strategies to obtain:

  • Late-stage assets.
  • Platform technologies.
  • Antibody or cell-line capabilities.
  • Delivery devices.
  • Regional rights.
  • Biosimilar portfolios.
  • Generic or authorized-generic channels.

Licensing contracts may include upfront payments, development milestones, royalties, manufacturing rights, territorial splits and options to acquire.

How does Medicare price negotiation affect branded drug exclusivity?

The Inflation Reduction Act created a Medicare drug-price negotiation program for selected high-spending products without generic or biosimilar competition. The first negotiated prices apply in 2026 to ten Part D drugs. The program expands to additional products in subsequent years (CMS, 2024b).

The commercial effect is greatest for mature blockbusters with:

  • High Medicare utilization.
  • No approved generic or biosimilar.
  • Long post-launch revenue tails.
  • Limited therapeutic substitution.
  • High annual treatment costs.

The statute creates incentives for earlier generic and biosimilar competition, lifecycle planning and launch sequencing. It also reduces the value of extending exclusivity through marginal reformulations that do not materially change clinical use.

What generic entry risks exist for branded products?

A branded product faces five principal entry risks:

  1. A successful Paragraph IV challenge against a composition, formulation or method-of-use patent.
  2. An authorized generic launched before independent generic entry.
  3. Multiple generic approvals after the 30-month stay expires.
  4. Biosimilar or interchangeable biosimilar substitution.
  5. Payer-driven switching before legal exclusivity fully expires.

Revenue erosion is usually fastest for conventional oral products with several generic competitors. Declines may be slower for injectable products, complex formulations, specialty products and biologics because manufacturing and substitution barriers limit the number of entrants.

How strong is a pharmaceutical patent estate?

Patent strength should be measured by commercial blocking power rather than patent count.

Factor Strong position Weak position
Core composition claim Broad, enabled and difficult to design around Narrow or vulnerable to prior art
Filing chronology Early priority date and reliable continuity Late lifecycle filing
Formulation dependency Product performance requires claimed formulation Easy alternative formulation
Method-of-use claim Necessary indication and label protection Easily omitted through skinny labeling
Manufacturing process Difficult, secretive or technically essential Publicly reproducible process
Litigation record Claims survive validity challenges Adverse claim construction or invalidity ruling
Regulatory linkage Patent listed and relevant to approved use Not listable or delisted
Competitor complexity Few capable manufacturers Many approved competitors

Geographic coverage also matters. U.S. patent rights do not control entry in Europe, Canada, Japan or emerging markets. A global launch plan must map national patent families, supplementary protection certificates, data exclusivity, biosimilar rules and local compulsory-license exposure.

What manufacturing and intellectual-property barriers limit generic entry?

Manufacturing barriers are often more durable than ordinary formulation patents. They include:

  • High-potency or cytotoxic handling.
  • Sterile fill-finish capacity.
  • Complex aseptic processing.
  • Specialized API synthesis.
  • Peptide or oligonucleotide production.
  • Cell-line development.
  • Viral-vector manufacturing.
  • Device assembly and human-factors validation.
  • Limited qualified suppliers.
  • Restricted analytical reference standards.
  • Technology-transfer constraints.

FDA drug shortages have highlighted the vulnerability of sterile injectables and products made by a small number of facilities. Companies that can provide reliable manufacturing, redundant sites and validated analytical methods may obtain better commercial access than competitors with lower nominal pricing but weaker supply reliability.

What are the principal regulatory and commercial challenges?

The leading challenges are:

  • FDA review delays for complex generics.
  • Incomplete or disputed Orange Book listings.
  • Patent thickets and serial continuation filings.
  • Paragraph IV litigation costs.
  • Antitrust exposure from settlement agreements.
  • Biologic manufacturing scale-up.
  • Interchangeability and substitution limits.
  • Medicare price negotiation.
  • Medicaid best-price obligations.
  • 340B purchasing pressure.
  • Pharmacy benefit manager rebate structures.
  • Drug shortages and supply-chain concentration.
  • State substitution and pharmacy laws.
  • Foreign reference-product and import requirements.
  • Environmental, serialization and pharmacovigilance obligations.

Commercial viability depends on approval timing, expected competitor count, payer access, manufacturing cost, launch inventory and litigation outcomes. A technically approvable product may still fail economically if several competitors launch simultaneously or if a major payer excludes it.

Key takeaways

  • Generics dominate U.S. prescription volume, while brands and biologics capture most spending.
  • Composition patents remain the strongest form of protection, but formulation, device, method-of-use and manufacturing patents can delay entry.
  • Paragraph IV challenges create the main route to early generic entry.
  • The 30-month stay can delay approval but does not guarantee continued market exclusivity.
  • Biosimilars face higher technical and commercial barriers than conventional generics.
  • FDA policy favors competition in complex generics, shortage-prone products and products with limited competition.
  • Orange Book review must be combined with litigation, patent-family and regulatory-exclusivity analysis.
  • Medicare negotiation reduces the value of long late-life exclusivity for high-spend products.
  • Patent strength depends on enforceability and commercial blocking power, not patent count.
  • The best generic opportunities are often complex products with few competitors and significant manufacturing barriers.

FAQs about the U.S. branded and generic drug markets

How long does a generic drug remain under FDA review?

Review time varies by product complexity, application quality, facility status, manufacturing questions and FDA workload. Standard ANDA review is subject to FDA performance goals, but deficiencies and facility issues can extend the process.

Can a generic launch before every Orange Book patent expires?

Yes. Entry may occur after a successful Paragraph IV challenge, under a settlement license, through a court ruling, or after the relevant patent is found invalid, unenforceable or not infringed.

Does a method-of-use patent always block a generic?

No. A generic may use a skinny label that omits the patented indication if the remaining label supports approval and the product does not induce infringement.

Are biosimilars automatically substituted for biologics?

No. Automatic substitution depends on FDA interchangeability designation and applicable state pharmacy law. Payers and prescribers may still drive nonautomatic switching.

Can an authorized generic reduce the value of 180-day generic exclusivity?

Yes. An authorized generic can create price competition during the first-filer’s 180-day period, although the legal and commercial effects depend on the launch structure and applicable agreements.

References

Centers for Medicare & Medicaid Services. (2024a). National health expenditure data: Historical. https://www.cms.gov/data-research/statistics-trends-and-reports/national-health-expenditure-data

Centers for Medicare & Medicaid Services. (2024b). Medicare drug price negotiation program. https://www.cms.gov/inflation-reduction-act-and-medicare/medicare-drug-price-negotiation

Federal Trade Commission. (2024a). Pay-for-delay and reverse payment settlements. https://www.ftc.gov

Federal Trade Commission. (2024b). FTC initiatives concerning pharmaceutical patent listings. https://www.ftc.gov

U.S. Food and Drug Administration. (2024a). Generic drug facts. https://www.fda.gov/drugs/generic-drugs

U.S. Food and Drug Administration. (2024b). FDA and FTC actions concerning improper patent listings. https://www.fda.gov

U.S. Food and Drug Administration. (2024c). Competitive generic therapy. https://www.fda.gov/drugs/abbreviated-new-drug-application-anda/competitive-generic-therapy

U.S. Supreme Court. (2013). Federal Trade Commission v. Actavis, Inc., 570 U.S. 136. https://supreme.justia.com/cases/federal/us/570/136/

More… ↓

⤷  Start Trial

DrugPatentWatch cited by CNN, NEJM, Nature Journals, and more …

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

 
© Copyright 2002-2026 thinkBiotech LLC
ISSN: 2162-2639
Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2026 - 2027
 NCE-1 Patent Challenge Dates 2026 - 2027
Preferred Citation:

Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
   See Primary Research Papers Citing DrugPatentWatch

Links